RARE CANCERGynecologicWHO 5th Edition Classification

Vaginal Cancer

Rare Malignancy (< 6 cases per 100,000 / year) • Clinical Staging, Genomic Targets & Vetted Specialists

A rare gynaecological cancer arising primarily in the vagina rather than spreading there from the cervix or vulva - a distinction that must be made before the diagnosis is accepted. Most are HPV-related squamous cell carcinomas. Clear cell adenocarcinoma of the vagina has a specific historical association with in-utero diethylstilbestrol exposure.

Request Rare Cancer Tumor Board Find NCI Treatment CentersAsk Vani AI Navigator

Emergent Referral AdvisoryImmediate Action

Certain rare malignancies progress rapidly or carry acute risk of airway obstruction, acute spinal compression, hydrocephalus, or biopsy-seeding. Do not perform needle biopsy or surgery outside of an NCI-designated specialty sarcoma or neuro-oncology unit without multidisciplinary tumor board review.

Report immediately to an emergency department or tertiary oncologist upon:

  • Exclude cervical and vulval primaries before diagnosing primary vaginal cancer
Who It Affects

Women over 60 for squamous disease; young women for DES-related clear cell adenocarcinoma

Annual Incidence

Approximately 0.6-1 per 100,000 women per year

Clinical Evidence Review

Last audited: 2026-08-13 against NCCN, ESMO, and WHO 5th ed. guidelines.

Clinical Presentation & Hallmark Symptoms

Presenting signs most frequently observed across clinical case series

Abnormal vaginal bleeding, including after intercourse or after menopause
Watery, blood-stained or offensive discharge
A mass or lump felt in the vagina
Pain during intercourse or in the pelvis
Urinary symptoms or constipation with advanced disease

Genomic Profiling & Defining Molecular Lesions

Critical diagnostic fusions, somatic mutations, and therapeutic targets

Rare malignancies frequently depend on distinct oncogenic drivers rather than conventional environmental carcinogens. Comprehensive Next-Generation Sequencing (NGS comprehensive panel) and FISH/IHC are mandatory to establish the true diagnosis and screen for basket trial agents.

HPV 16/18 with p16 positivityPIK3CATP53

Standard-of-Care Treatment Protocol

Frontline and multimodal strategies established under international consensus guidelines

1

Definitive chemoradiotherapy with brachytherapy - the standard for most stages

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

2

Radical surgery for selected early upper-vaginal tumours

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

3

Brachytherapy alone for very early superficial disease

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

4

Cisplatin-based concurrent chemotherapy

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

5

Vaginal dilator therapy and survivorship support for stenosis and sexual function

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

Clinical Trial Advisory: For rare and ultra-rare malignancies, enrollment in an active clinical trial or expanded-access program is widely considered the preferred standard of care by ASCO and NCCN panels.

Prognosis & Disease Trajectory

Objective clinical outlook without false reassurance

Stage-dependent. Five-year survival is roughly 75-85% for stage I but falls substantially with pelvic sidewall involvement or nodal spread. Overall five-year survival across all stages is around 50%.

Note: Statistics reflect cohort averages. Individual outcomes depend heavily on performance status, resectability, biomarker expression, and timely access to specialized tertiary care.

Active Research, Biomarkers & Clinical Trials

Novel investigational agents, phase I/II trials, and international rare disease consortia

Image-guided adaptive brachytherapy has improved local control meaningfully; immunotherapy in recurrent HPV-associated disease is under study, largely extrapolated from cervical cancer trials given the rarity.

Need Help Matching to an Active Rare Cancer Trial?

ByOnco scans ClinicalTrials.gov, NCI trial networks, and institutional registries for open patient cohorts.

Request Trial Match
Expert Clinicians

Verified Specialists for Vaginal Cancer

Browse All Oncologists

Dr. Sarah M. Temkin

Gynecologic Oncologist

20+ yrs exp

Case Western/Seidman Cancer Center

Cleveland, USA

Gynecologic OncologyVaginal CancerBrachytherapy
Vetted DirectoryConsult Specialist

Dr. Lim Lay Hoon

Radiation Oncologist

15+ yrs exp

NCIS

Singapore, Singapore

Radiation OncologyGynecologic BrachytherapyInterstitial Implants
Vetted DirectoryConsult Specialist

Prof. Ignace Vergote

Gynecologic Oncologist

35+ yrs exp

University Hospital Leuven

Leuven, Belgium

Gynecologic OncologyRare Vaginal CancersEuropean Guidelines
Vetted DirectoryConsult Specialist

Dr. Swapna Misra

Gynecologic Oncologist

20+ yrs exp

KEM Hospital

Mumbai, India

Gynecologic OncologyVaginal CancerMultidisciplinary Care
Vetted DirectoryConsult Specialist
Hospital Network

Designated Cancer Centers with Dedicated Programs

Search All 72 NCI Centers

Memorial Sloan Kettering Cancer Center

NY

NCI-Designated Comprehensive Cancer Center

World-leading rare tumor board & pediatric solid tumor protocols

Proton TherapyCAR-T Cell TherapyRobotic Surgery
1,000+ Active Clinical TrialsView Center Profile

University of Texas MD Anderson Cancer Center

TX

NCI-Designated Comprehensive Cancer Center

Largest specialized rare cancer and sarcoma multidisciplinary program

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
1,200+ Active Clinical TrialsView Center Profile

Dana-Farber / Harvard Cancer Center

MA

NCI-Designated Comprehensive Cancer Center

Pioneering genomic molecular tumor boards & rare histologies

Proton TherapyCAR-T Cell TherapyPhase I Unit
1,100+ Active Clinical TrialsView Center Profile

Mayo Clinic Comprehensive Cancer Center

MN

NCI-Designated Comprehensive Cancer Center

High-volume surgical oncology & rare endocrine/neuroendocrine expertise

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
600+ Active Clinical TrialsView Center Profile

Frequently Asked Clinical Questions

Authoritative guidance on diagnosis, tumor boards, genomic markers, and care options

Related Rare Malignancies in Catalog

rare

Cancer of Unknown Primary (CUP)

rare

Malignant Mesothelioma

rare

Retinoblastoma

rare

Ewing Sarcoma

Independent Tumor Board Review

Facing a Diagnosis of Vaginal Cancer?

Rare cancers demand rare expertise. Connect your medical records to US NCI-fellowship trained oncologists, subspecialist pathologists, and active clinical trial investigators within 12 to 72 hours.

Upload Scans for Second Opinion Schedule Virtual Teleconsult